The initiation of a Phase IIa clinical trial of ICCOV, a COVID-19 DNA vaccine candidate. The clinical trial is initiated by Immuno Cure in collaboration with the University of Hong Kong (“HKU”) and will be conducted in Gleneagles Hospital Hong Kong.
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS
Immuno Cure appoints new CFO
Strengthening of executive management team to propel growth strategy
Immuno Cure secured maximum subsidy from HKSTP
Significant funding support for HIV Vaccine Clinical Trial
Immuno Cure BioTech acquires Shanghai Teresa Healthcare
Integrating Electroporation Technology & DNA Vaccine Platforms
Acquisition of 92.6% of Shanghai Teresa Healthcare
Immuno Cure BioTech appoints new CEO
Broadening executive leadership team to accelerate growth strategy
Dr. Xia Jin appointed as new Chief Executive Officer and Executive Director of our Group